Xtant Medical Launches Next-Generation Synthetic Bone Graft Designed for Superior Biointegration
Published: 12 Dec 2025
Author: Precedence Research
Xtant Medical Holdings, Inc., a premier manufacturer of superior surgical devices in spinal and orthopaedic surgery, has announced the launch of its latest synthetic bone graft, nanOss Stratatm. Strata has been designed to provide better biological performance, improved handling, and greater versatility to surgeons who require reliable grafting solutions for a variety of more complex procedures. As the trend toward synthetic graft substitutes approaches those that most closely mimic natural bone behaviour, Strata is poised to play a significant role in regenerative medicine and spinal reconstruction.
NanoOss Strata, unlike traditional synthetic grafts, is made from hydroxycarbonapatite (HCA). This material is particularly chosen for its increased solubility, nanocrystalline character, and better ability to facilitate bone remodeling. With this composition, strata can resorb more effectively over time, helping them integrate more effectively with the host bone and promoting faster healing. Xtant Medical notes that these material benefits help surgeons achieve a more predictable fusion environment. The company has placed significant attention on research into materials that not only provide structural gain but also actively support the healing of natural bones.
The focus on nanotechnology and biomimetic materials is a long-term investment for Xtant Medical in regenerative medicine. Strata can improve nanoscale engineering of the graft by mimicking the morphology of human bone to increase cellular contact surface area. This further supports a biologically favorable microenvironment conducive to healthy bone regeneration. This method aligns with current trends in orthopedic biomaterials. Additionally, the launch of Strata will help Xtant Medical establish a stronger presence as a leading competitor in the synthetic graft market.
Executive Statement
Sean Browne, President & CEO, Xtant Medical
“By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve their patients' surgical outcomes. Strata represent not just an expansion of our portfolio but a meaningful step forward in our mission to bring scientifically advanced, accessible grafting solutions to orthopedic care worldwide.”